Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Coverage evaluation of mass drug administration with triple drug regimen in an evaluation unit in Nagpur district of Maharashtra, India.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: Public Library of Science Country of Publication: United States NLM ID: 101291488 Publication Model: eCollection Cited Medium: Internet ISSN: 1935-2735 (Electronic) Linking ISSN: 19352727 NLM ISO Abbreviation: PLoS Negl Trop Dis Subsets: MEDLINE
- Publication Information:
Original Publication: San Francisco, CA : Public Library of Science
- Subject Terms:
- Abstract:
Background: Triple drug regimen (IDA; Ivermectin, Diethylcarbamazine, Albendazole) recommended for accelerating elimination of lymphatic filariasis was launched in India in December 2018. Nagpur district in Maharashtra was one of the first five districts where this strategy was introduced. The National Vector Borne Disease Control Programme (NVBDCP) at the district reported ~85.0% treatment coverage in the first round of mass drug administration (MDA) with IDA implemented in EU-2 in Nagpur district in January 2019. As per the national guideline, a coverage evaluation survey was carried out and both quantitative and qualitative data were collected to assess the treatment coverage, the level of community preparation and identify the gaps, if any, for improvement.
Methodology: A Coverage Evaluation Survey (CES) following the WHO recommended protocol was conducted in one of the two evaluation units (EU-2) in Nagpur district in March 2019. Coverage Sample Builder (CSB) V2.9 tool was used to calculate the sample size, select sites and estimate drug coverage. The CSB tool followed a two-stage cluster sampling procedure to select 30 primary sampling units (ward/village as a cluster) and a list of random numbers for selecting households (HHs) in each cluster. The results were analyzed for operational indicators. Stata ver. 14.0 software was used to construct the 95% confidence limits accounting for clustering.
Results: A total of 1601 individuals aged 5-85 years of both gender from 328 HHs were surveyed from the 30 randomly selected clusters in EU-2. The mean age was 33.8±17.6 years. Among the surveyed population, 78.0% received the drugs (programme reach) and 66.1% consumed the drugs (survey coverage). Survey coverage was significantly higher in rural (82.6%) than in urban (59.4%) and peri-urban (58.6%) areas (P<0.001). Directly observed treatment (DOT) among the surveyed population was 51.6%. Adverse events were reported among 6.9% respondents who reported to have consumed the drugs.
Conclusion: The IDA based MDA strategy could achieve just the required level of treatment coverage (~65%) in EU-2, Nagpur district, which had previously undergone several rounds of DA-MDAs (Diethylcarbamazine, Albendazole). Having achieved an effective treatment coverage of >80% in rural areas, the coverage in urban and peri-urban areas need to be improved in order to attain the impact of IDA-MDA. It is imperative to strengthen drug delivery and community preparation activities along with improved DOT especially in urban and peri-urban areas to achieve the required level of treatment coverage. Addition of ivermectin did not have any additional perceived adverse events.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2023 Dinesh et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- References:
Lancet Infect Dis. 2017 Apr;17(4):451-458. (PMID: 28012943)
Am J Trop Med Hyg. 2022 Mar 15;106(5_Suppl):29-38. (PMID: 35292580)
PLoS Negl Trop Dis. 2021 Feb 16;15(2):e0009069. (PMID: 33591979)
PLoS Negl Trop Dis. 2021 Mar 3;15(3):e0009002. (PMID: 33657090)
PLoS Med. 2019 Jun 24;16(6):e1002839. (PMID: 31233507)
PLoS Negl Trop Dis. 2013 Nov 21;7(11):e2447. (PMID: 24278486)
J Family Med Prim Care. 2019 Sep 30;8(9):3009-3014. (PMID: 31681683)
N Engl J Med. 2020 May 14;382(20):1956-1957. (PMID: 32402169)
Gates Open Res. 2019 Sep 13;3:1538. (PMID: 31728440)
PLoS Negl Trop Dis. 2020 Nov 30;14(11):e0008854. (PMID: 33253148)
- Accession Number:
F4216019LN (Albendazole)
V867Q8X3ZD (Diethylcarbamazine)
70288-86-7 (Ivermectin)
- Publication Date:
Date Created: 20230907 Date Completed: 20230911 Latest Revision: 20230930
- Publication Date:
20250114
- Accession Number:
PMC10484419
- Accession Number:
10.1371/journal.pntd.0011588
- Accession Number:
37676897
No Comments.